Ivonescimab HARMONi trial shows improved OS trend in longer follow-up; North American HR=0.70

Summit Therapeutics Inc.

Longer-term follow-up of Western patients: OS HR=0.78 (nominal p=0.0332); median OS 16.8 vs 14.0 months.
North American patients: median OS not reached for ivonescimab vs 14.0 months for placebo (HR=0.70).
Primary PFS analysis showed HR=0.52 (p<0.00001); median PFS 6.8 vs 4.4 months.
Overall response rate higher with ivonescimab (45% vs 34%); median duration of response 7.6 vs 4.2 months.
Safety profile manageable; TRAEs leading to discontinuation 7.3% (ivonescimab) vs 5.0% (placebo).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.